Saturn V Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Saturn V Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-37,432	Closed	-$2.63M	–	25
2024 Q3	$2.63M	Sell	37,432 -141,157	-79%	-$11.8M	0.94%	21
2024 Q2	$14.7M	Buy	178,589 +59,401	+50%	+$4.95M	5.56%	7
2024 Q1	$10.4M	Hold	119,188	–	–	4.17%	12
2023 Q4	$11.5M	Buy	119,188 +9,503	+9%	+$841K	4.4%	9
2023 Q3	$9.7M	Buy	109,685 +17,059	+18%	+$1.52M	4.06%	14
2023 Q2	$8.03M	Buy	+92,626	New	+$8.72M	4.45%	12

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Saturn V Capital Management's BMRN Position: Q4 2024 in Review

Saturn V Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 37,432 shares — an estimated $2.63M sold.

Saturn V Capital Management first reported a position in BMRN in Q2 2023 and held it in 6 quarters. The position peaked at $14.7M in Q2 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Saturn V Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Saturn V Capital Management sold 37,432 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $2.63M.
Saturn V Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 6 quarters.
Saturn V Capital Management's BioMarin Pharmaceuticals position peaked at $14.7M in Q2 2024.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Saturn V Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.